Skip to main content
ELVN
NASDAQ Life Sciences

Enliven Posts Q3 Loss, $884M Cash and Runway Into 2030 Ahead of ENABLE-2 Launch

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$44.79
Mkt Cap
$3.282B
52W Low
$14.785
52W High
$62.32
52W Position info
203% above low
Off High info
28% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

ELVN has more than doubled off its 52-week low of $14.785.

Summary

Enliven reported a $27.7 million third-quarter net loss but finished September with $884.4 million in cash and securities, extending its runway into 2030 as it prepares to start the pivotal ENABLE-2 trial before year-end.


Key Events · Earnings and Guidance · ELVN

  • Q3 Loss Widens on Phase 3 Prep

    Net loss was $27.7 million, or $0.36 per share, versus $20.1 million a year earlier, as R&D rose to $28.0 million from $18.2 million.

  • Cash Runway Extended Into 2030

    Cash, cash equivalents and marketable securities totaled $884.4 million at September 30, 2026, up from $462.6 million at December 31, 2025, funding operations into 2030.

  • ENABLE-2 Design Finalized With FDA

    The pivotal Phase 3 will enroll about 450 previously treated CML patients, randomized 1:1 to relcobatinib 80 mg daily or an investigator-selected second-generation TKI, with MMR at Week 24 as the primary endpoint.

  • Trial Start Targeted Before Year-End

    Enliven says it remains on track to initiate ENABLE-2 before year-end 2026; the FDA alignment itself was already disclosed on October 7.


Analysis · ELVN · Life Sciences

Financial strength, not the loss, is the quarter's headline: $884.4 million in cash and securities now funds operations into 2030, roughly a year beyond the runway into the first half of 2029 disclosed in the prior 10-Q. For a company spending about $36 million a quarter, that removes any near-term financing need, so shareholders face no dilution overhang while the pivotal ENABLE-2 trial runs. The FDA alignment on ENABLE-2 was already public on October 7; what is new here is the trial's concrete shape (about 450 patients, 1:1 against a second-generation TKI, MMR at Week 24 as the accelerated-approval endpoint) and confirmation that initiation is still expected before year-end 2026. Rising R&D spend ($28.0 million vs $18.2 million) is the expected cost of moving into Phase 3, not a warning.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 35.2% of the 2649 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ELVN was trading at $44.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.3B. The 52-week trading range was $14.79 to $62.32. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ELVN - Latest Insights

ELVN
Nov 05, 2026, 4:15 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $44.79
Real-time Price: $44.79 info
Change: $0 (0%) info
Market Cap: $3.282B info
ELVN
Oct 06, 2026, 11:12 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $42.39
Real-time Price: $44.79 info
Change: +$2.40 (+6%) info
Market Cap: $3.282B info
ELVN
Jun 24, 2026, 7:15 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $47.60
Real-time Price: $44.79 info
Change: -$2.81 (-6%) info
Market Cap: $3.282B info
ELVN
Jun 22, 2026, 8:10 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $45.37
Real-time Price: $44.79 info
Change: -$0.580 (-1%) info
Market Cap: $3.282B info
ELVN
Jun 15, 2026, 9:21 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $42.60
Real-time Price: $44.79 info
Change: +$2.19 (+5%) info
Market Cap: $3.282B info